Loading...

KROS KEROS THERAPEUTICS INC Company Mergers 8-K Filing

KRS

KRS

KEROS THERAPEUTICS INC

(KROS)

2024 8-K

Show Summary

Show Summary

Management Changes

Financial Statements

Board Nominations

Clinical Trial Results

Bylaw Amendments

Conference Participation

Financial Results

Conference Announcement

License Agreement

Corporate Update

Trial Dosing Halt

Clinical Trial Update

License Agreement

Conference Participation

Quarterly Results

Conference Announcement

Management Change

Trial Enrollment Update

TROPOS Trial Update

Conference Participation

Presentation Update

Earnings Reports

Sales Agreement

Transition of Executives

Clinical Trial Results

Investor Conferences

Annual Meeting of Stockholders

Appointment of Director

Earnings Reports

FDA Fast Track Designation ...

Presentation Update

Resignation of Chief Medica...

Financial Results Announcement

Public Offering

Underwriting Agreement

Corporate Presentation and ...

Additional Data from Phase ...

Announcement of CEO Partici...

Regulation FD Disclosure

Results of Operations and F...

Presentation Update

Earnings Reports

Investor meetings

Clinical Trial Data Announc...

Conference Presentation

Annual Meeting of Stockholders

Financial Results Announcement

Appointment of Director

Earnings Report

Regulation FD Disclosure

Regulation FD Disclosure

Lease Amendment

External Links:

Keros Therapeutics entered into an Exclusive License Agreement with Takeda Pharmaceuticals, granting Takeda the rights to develop and commercialize elritercept, with an upfront payment of $200 million and potential milestone payments totaling up to $

AI Assistant

KEROS THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.